Hendley & Co. Inc. Has $5 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Hendley & Co. Inc. decreased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 49.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 30,132 shares of the company's stock after selling 29,297 shares during the period. Johnson & Johnson comprises 1.7% of Hendley & Co. Inc.'s portfolio, making the stock its 18th biggest position. Hendley & Co. Inc.'s holdings in Johnson & Johnson were worth $4,997,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of JNJ. WealthTrak Capital Management LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in Johnson & Johnson during the 4th quarter worth $29,000. Conquis Financial LLC acquired a new position in Johnson & Johnson in the fourth quarter valued at about $33,000. Bernard Wealth Management Corp. bought a new stake in Johnson & Johnson during the 4th quarter worth approximately $36,000. Finally, Highline Wealth Partners LLC lifted its position in Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after acquiring an additional 86 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Trading Up 0.3%

Shares of JNJ stock traded up $0.49 during trading hours on Tuesday, hitting $155.76. 6,432,327 shares of the company's stock traded hands, compared to its average volume of 8,046,146. The stock's 50 day simple moving average is $153.67 and its 200 day simple moving average is $154.24. The stock has a market cap of $374.77 billion, a PE ratio of 17.33, a price-to-earnings-growth ratio of 2.36 and a beta of 0.41. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The company had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.34%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio (DPR) is presently 57.84%.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of recent research reports. Wall Street Zen upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, June 21st. Raymond James Financial lowered their price objective on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research note on Monday, April 14th. Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Barclays cut their price objective on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a report on Thursday, April 17th. Finally, Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Eleven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $170.88.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.